The Need for Improved Therapeutic Strategies for Patients with Metastatic Hormone-Refractory Prostate Cancer

European Urology, Supplements

Volumn 5, Issue 15, 2006, Pages 811-816

  Anderson, John ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Docetaxel; Hormone refractory prostate cancer; HRPC; Multidisciplinary; TAX 327

Indexed keywords

AMINOGLUTETHIMIDE; ANTIANDROGEN; BICALUTAMIDE; DEXAMETHASONE; FLUTAMIDE; FOSFESTROL; HYDROCORTISONE; KETOCONAZOLE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ANDROGEN THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; HUMAN; METASTASIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 33747816095     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.06.016     Document Type: Review

References (42)

1. Bono A.V. The global state of prostate cancer: epidemiology and screening in the second millennium. BJU Int 94 (2004) 1-2
2. Beedassy A., and Cardi G. Chemotherapy in advanced prostate cancer. Semin Oncol 26 (1999) 428-438
3. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
4. Boyle P., and Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 16 (2005) 481-488
5. Paquette E.L., Sun L., Paquette L.R., Connelly R., McLeod D.G., and Moul J.W. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 60 (2002) 756-759
6. Tarone R.E., Chu K.C., and Brawley O.W. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 11 (2000) 167-170
7. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 281 (1999) 1598-1604
8. Zincke H., Oesterling J.E., Blute M.L., Bergstralh E.J., Myers R.P., and Barrett D.M. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152 (1994) 1850-1857
9. Lam J.S., Leppert J.T., Vemulapalli S.N., Shvarts O., and Belldegrun A.S. Secondary hormonal therapy for advanced prostate cancer. J Urol 175 (2006) 27-34
10. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
11. D'Amico A.V., Moul J., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21 (2003) 2163-2172
12. NICE. Guidance on Cancer Services. Improving outcomes in urological cancers (2002)
13. Deutsch E., Maggiorella L., Eschwege P., Bourhis J., Soria J.C., and Abdulkarim B. Environmental, genetic, and molecular features of prostate cancer. Lancet Oncol 5 (2004) 303-313
14. Arnold J.T., and Isaacs J.T. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 9 (2002) 61-73
15. Kish J.A., Bukkapatnam R., and Palazzo F. The treatment challenge of hormone-refractory prostate cancer. Cancer Control 8 (2001) 487-495
16. Gleave M.E., La Bianca S.E., Goldenberg S.L., Jones E.C., Bruchovsky N., and Sullivan L.D. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. Urology 56 (2000) 289-294
17. Chodak G.W., Keane T., and Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 60 (2002) 201-208
18. Ryan C.J., and Eisenberger M. Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?". J Clin Oncol 23 (2005) 8242-8246
19. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339 (1998) 1036-1042
20. Diaz M., and Patterson S.G. Management of androgen-independent prostate cancer. Cancer Control 11 (2004) 364-373
21. Scher H.I., and Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 55 (2000) 323-327
22. Sternberg C.N. Highlights of contemporary issues in the medical management of prostate cancer. Crit Rev Oncol Hematol 43 (2002) 105-121
23. Newling D., Fossa S.D., Andersson L., et al. Assessment of hormone refractory prostate cancer. Urology 49 (1997) 46-53
24. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
25. Aus G, Abbou C, Bolla M, et al. EAU guidelines on prostate cancer. Available online at http://www.uroweb.nl/files/uploaded_files/2005ProstateCancer.pdf 2005.
26. Martel C.L., Gumerlock P.H., Meyers F.J., and Lara P.N. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 29 (2003) 171-187
27. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
28. Shulman M.J., and Benaim E.A. The natural history of androgen independent prostate cancer. J Urol 172 (2004) 141-145
29. Halabi S., Small E.J., Kantoff P.W., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 (2003) 1232-1237
30. Scher H.I., Liebertz C., Kelly W.K., et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 15 (1997) 2928-2938
31. Joyce R., Fenton M.A., Rode P., et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 159 (1998) 149-153
32. Kassouf W., Tanguay S., and Aprikian A.G. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 169 (2003) 1742-1744
33. Desai A., Stadler W.M., and Vogelzang N.J. Nilutamide: possible utility as a second-line hormonal agent. Urology 58 (2001) 1016-1020
34. Scher H.I., Zhang Z.F., Nanus D., and Kelly W.K. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology 47 (1996) 61-69
35. Small E.J., Baron A.D., Fippin L., and Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 157 (1997) 1204-1207
36. Morioka M., Kobayashi T., Furukawa Y., et al. Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone. Urol Int 68 (2002) 10-15
37. Orlando M., Chacon M., Salum G., and Chacon D.R. Low-dose continuous oral fosfestrol is highly active in 'hormone-refractory' prostate cancer. Ann Oncol 11 (2000) 177-181
38. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458-1468
39. Berthold D.R., Sternberg C.N., and Tannock I.F. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 23 (2005) 8247-8252
40. Jager P.L., Kooistra A., and Piers D.A. Treatment with radioactive (89)strontium for patients with bone metastases from prostate cancer. BJU Int 86 (2000) 929-934
41. Pienta K.J., and Smith D.C. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 55 (2005) 300-318 quiz 323-305
42. Yagoda A., and Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71 (1993) 1098-1109